

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5541204

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JOHN FRITIOF PONTEN	02/18/2015
HANS ROLAND LONN	02/21/2015
CARL-JOHAN AURELL	03/03/2015
STAFFAN PO KARLSSON	03/03/2015
RECEIVING PARTY DATA	
Name:	ASTRAZENECA AB
Street Address:	SE-151 85
City:	SODERTALJE
State/Country:	SWEDEN
Postal Code:	SE-151 85
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16358091
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2028427800
Email:	zIPPatentDocketingMailboxUS@cooley.com, sbittler@cooley.com
Correspondent Name:	COOLEY LLP
Address Line 1:	ATTN: PATENT GROUP
Address Line 2:	1299 PENNSYLVANIA AVENUE, SUITE 700
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	INMD-132/04US 315953-3647
NAME OF SUBMITTER:	SANDHYA DEO
SIGNATURE:	/Sandhya Deo/
DATE SIGNED:	05/26/2019
Total Attachments: 9	
source=Assignment #1#page9.tif	
source=Assignment #1#page10.tif	

source=Assignment #1#page11.tif
source=Assignment #1#page12.tif
source=Assignment #1#page13.tif
source=Assignment #1#page14.tif
source=Assignment #1#page15.tif
source=Assignment #1#page16.tif
source=Assignment #1#page17.tif

ASSIGNMENT OF INVENTION MADE DURING EMPLOYMENT

§1

The undersigned, Hans Ronald LÖNN (SE citizen); Stephen CONNOLLY (GB citizen); and John Fritiof PONTÉN (SE citizen) all c/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire, SK10 4TG United Kingdom as of the 23rd day of January 2015 (the "Effective Date") hereby confirm(s) that by virtue of their employment have assigned and do hereby assign to AstraZeneca AB with registered office address at SE-151 85 Södertälje, Sweden (the "Assignee") an invention (as further defined below) made during employment, which invention, in accordance with the rules laid down in the collective bargaining agreement between SAF (the Swedish Employers' Confederation) and PTK (the Swedish Federation of Salaried Employees in Industry and Services) dated 1 April, 1995, has been brought to the attention of the employer and has been categorized as a Class A Invention. The Inventor(s) further acknowledge that insofar as and solely to the extent that the Rights apply to India, the amount paid to the Inventor(s) pursuant to their contract of employment includes nominal consideration of 10 SEK.

§2

This assignment comprises our entire right, title and interest to said invention made by me and to any and all patents that may be granted thereon.

§3

The assignment as stated in §2, above, includes, but is not restricted to, the right without limitation to apply for, to be granted and to assign patents and other means of protection of industrial property that may be granted on said invention, that is included in the patent application(s) specified in the attached Schedule (the "Patent Application(s)") with regard to the invention referred to by this confirmation for a patent, design registration or inventor's certificate or other comparable means of protection of industrial property, and the right to file a patent application anywhere in the world claiming convention priority

§4

I hereby confirm that calculation of the remuneration for the invention assigned to AstraZeneca AB and shall be subject to the rules stated in the directions, dated 10 February, 1984, as to providing incentives for inventors among employees of the AstraZeneca group of companies.

§5

The AstraZeneca group of companies are entitled at any time to waive their rights to the invention in favour of me/us, in which case any remuneration already paid out is not required to be refunded.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Signed at:

Date:

2015-02-18

 Name: John Fritiof PONTÉN

Witnessed by:


Name:

Margareta Eldng-PONTÉN
 MARGARETA ELDNG-PONTÉN

The above assignment agreement is accepted:


Signed at: Waltham MA USA

Date: 17 - Mar - 2015



Signed for on behalf of
ASTRAZENECA AB (PUBL)
Name: Meaghan RICHMOND
Title: Authorised Signatory

Witnessed by:



Name: Kalliopi Gantzoudis

THE SCHEDULE

THE PATENT APPLICATION(S)					
AstraZeneca Case No:	Application Ref:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
200167-AR-NP	A	Argentina	National	20150100202	23 Jan 2015
200167-BO-NP	B	Bolivia	National	SP00006-2015	23 Jan 2015
200167-WO-PCT	C	International	PCT	PCT/GB2015/050155	23 Jan 2015
200167-LB-NP	D	Lebanon	National	10549	23 Jan 2015
200167-PY-NP	E	Paraguay	National	2227/2015	27 Jan 2015
200167-PK-NP	F	Pakistan	National	12/2015	8 Jan 2015
200167-TW-NP	G	Taiwan	National	104102345	23 Jan 2015
200167-UY-NP	H	Uruguay	National	35963	23 Jan 2015
200167-US-NP	I	USA	National	14/601371	21 Jan 2015
200167-VE-NP	J	Venezuela	National	000067-2015	23 Jan 2015
200167-BS-NP	K*	Bahamas	National	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS	Not available yet
200167-JM-NP	L*	Jamaica	National	18/1/5647	07 Jan 2015

Patent Application(s) referenced A to J inclusive claim priority from the following US Provisional Application(s)

Application No.	Filing Date
61/931090	24 January 2014

Patent Application(s) referenced K* and L* do not claim priority

ASSIGNMENT OF INVENTION MADE DURING EMPLOYMENT

§1

The undersigned, ^{*Roland*} ~~Ronald~~ LÖNN (SE citizen); Stephen CONNOLLY (GB citizen); and John Fritiof PONTÉN (SE citizen) all c/o AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield Cheshire, SK10 4TG United Kingdom as of the 23rd day of January 2015 (the "Effective Date") hereby confirm(s) that by virtue of their employment have assigned and do hereby assign to AstraZeneca AB with registered office address at SE-151 85 Södertälje, Sweden (the "Assignee") an invention (as further defined below) made during employment, which invention, in accordance with the rules laid down in the collective bargaining agreement between SAF (the Swedish Employers' Confederation) and PTK (the Swedish Federation of Salaried Employees in Industry and Services) dated 1 April, 1995, has been brought to the attention of the employer and has been categorized as a Class A Invention. The Inventor(s) further acknowledge that insofar as and solely to the extent that the Rights apply to India, the amount paid to the Inventor(s) pursuant to their contract of employment includes nominal consideration of 10 SEK.

§2

This assignment comprises our entire right, title and interest to said invention made by me and to any and all patents that may be granted thereon.

§3

The assignment as stated in §2, above, includes, but is not restricted to, the right without limitation to apply for, to be granted and to assign patents and other means of protection of industrial property that may be granted on said invention, that is included in the patent application(s) specified in the attached Schedule (the "Patent Application(s)") with regard to the invention referred to by this confirmation for a patent, design registration or inventor's certificate or other comparable means of protection of industrial property, and the right to file a patent application anywhere in the world claiming convention priority

§4

I hereby confirm that calculation of the remuneration for the invention assigned to AstraZeneca AB and shall be subject to the rules stated in the directions, dated 10 February, 1984, as to providing incentives for inventors among employees of the AstraZeneca group of companies.


§5

The AstraZeneca group of companies are entitled at any time to waive their rights to the invention in favour of me/us, in which case any remuneration already paid out is not required to be refunded.


Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Signed at: *Harlösa*

Date: *21 February 2015*


Name: Hans Ronald LÖNN
Roland


Witnessed by:


Name: Anders Ahlqvist


The above assignment agreement is accepted:

Signed at: Waltham MA USA

Date: 17-Mar-2015


Signed for on behalf of
ASTRAZENECA AB (PUBL)
Name: Meaghan RICHMOND
Title: Authorised Signatory

Witnessed by:


Name: Kalliopi Gantzoudis

THE SCHEDULE

THE PATENT APPLICATION(S)					
AstraZeneca Case No:	Application Ref:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
<u>200167-AR-NP</u>	A	Argentina	National	20150100202	23 Jan 2015
<u>200167-BO-NP</u>	B	Bolivia	National	SP00006-2015	23 Jan 2015
<u>200167-WO-PCT</u>	C	International	PCT	PCT/GB2015/050155	23 Jan 2015
<u>200167-LB-NP</u>	D	Lebanon	National	10549	23 Jan 2015
<u>200167-PY-NP</u>	E	Paraguay	National	2227/2015	27 Jan 2015
<u>200167-PK-NP</u>	F	Pakistan	National	12/2015	8 Jan 2015
<u>200167-TW-NP</u>	G	Taiwan	National	104102345	23 Jan 2015
<u>200167-UY-NP</u>	H	Uruguay	National	35963	23 Jan 2015
<u>200167-US-NP</u>	I	USA	National	14/601371	21 Jan 2015
<u>200167-VE-NP</u>	J	Venezuela	National	000067-2015	23 Jan 2015
<u>200167-BS-NP</u>	K*	Bahamas	National	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS	Not available yet
<u>200167-JM-NP</u>	L*	Jamaica	National	18/1/5647	07 Jan 2015

Patent Application(s) referenced A to J inclusive claim priority from the following US Provisional Application(s)

Application No.	Filing Date
61/931090	24 January 2014

Patent Application(s) referenced K* and L* do not claim priority

ASSIGNMENT OF INVENTION MADE DURING EMPLOYMENT

§1

The undersigned, Carl-Johan AURELL (SE citizen) and Staffan PO KARLSSON (SE citizen) both of AstraZeneca R&D Mölndal SE-431 83 Mölndal, Sweden as of the 23rd day of January 2015 (the "**Effective Date**") hereby confirm(s) that by virtue of their employment have assigned and do hereby assign to AstraZeneca AB with registered office address at SE-151 85 Södertälje, Sweden (the "**Assignee**") an invention (as further defined below) made during employment, which invention, in accordance with the rules laid down in the collective bargaining agreement between SAF (the Swedish Employers' Confederation) and PTK (the Swedish Federation of Salaried Employees in Industry and Services) dated 1 April, 1995, has been brought to the attention of the employer and has been categorized as a Class A Invention. The Inventor(s) further acknowledge that insofar as and solely to the extent that the Rights apply to India, the amount paid to the Inventor(s) pursuant to their contract of employment includes nominal consideration of 10 SEK.

§2

This assignment comprises our entire right, title and interest to said invention made by us and to any and all patents that may be granted thereon.

§3

The assignment as stated in §2, above, includes, but is not restricted to, the right without limitation to apply for, to be granted and to assign patents and other means of protection of industrial property that may be granted on said invention, that is included in the patent application(s) specified in the attached Schedule (the "**Patent Application(s)**") with regard to the invention referred to by this confirmation for a patent, design registration or inventor's certificate or other comparable means of protection of industrial property, and the right to file a patent application anywhere in the world claiming convention priority

§4

I hereby confirm that calculation of the remuneration for the invention assigned to AstraZeneca AB and shall be subject to the rules stated in the directions, dated 10 February, 1984, as to providing incentives for inventors among employees of the AstraZeneca group of companies.

§5

The AstraZeneca group of companies are entitled at any time to waive their rights to the invention in favour of me/us, in which case any remuneration already paid out is not required to be refunded.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

Signed at: Mölndal, Sweden

Date: 2015-03-03



Name: Carl-Johan AURELL


Witnessed by:




Name:

Christina Fregler

Date: 2015-03-03


Name: Staffan PO KARLSSON

Witnessed by:


Name: Christina Fregler


The above assignment agreement is accepted:

Signed at: Waltham MA USA

Date: 17 March - 2015


Signed for on behalf of
ASTRAZENECA AB (PUBL)
Name: Meaghan RICHMOND
Title: Authorised Signatory

Witnessed by:


Name: Kalliopi Gantzoudis

THE SCHEDULE

THE PATENT APPLICATION(S)					
AstraZeneca Case No:	Application Ref:	Country	Filing Type	Application No. and/or Title of Invention	Filing Date
200167-AR-NP	A	Argentina	National	20150100202	23 Jan 2015
200167-BO-NP	B	Bolivia	National	SP00006-2015	23 Jan 2015
200167-ET-NP	C	Ethiopia	National	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS	Not available yet
200167-WO-PCT	D	International	PCT	PCT/GB2015/050155	23 Jan 2015
200167-LB-NP	E	Lebanon	National	10549	23 Jan 2015
200167-PY-NP	F	Paraguay	National	2227/2015	27 Jan 2015
200167-PK-NP	G	Pakistan	National	12/2015	8 Jan 2015
200167-TW-NP	H	Taiwan	National	104102345	23 Jan 2015
200167-UY-NP	I	Uruguay	National	35963	23 Jan 2015
200167-US-NP	J	USA	National	14/601371	21 Jan 2015
200167-VE-NP	K	Venezuela	National	000067-2015	23 Jan 2015
200167-BS-NP	L*	Bahamas	National	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS	Not available yet
200167-JM-NP	M*	Jamaica	National	18/1/5647	07 Jan 2015

Patent Application(s) referenced A to K inclusive claim priority from the following US Provisional Application(s)

Application No.	Filing Date
61/931090	24 January 2014

Patent Application(s) referenced L* and M* do not claim priority